ArticleFrontiers in medicine2025
Relationship between lung function impairment, clinical characteristics and systemic inflammation based on a large-scale population screening.
Article in Frontiers in medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Lung function impairment, a hallmark of chronic airway diseases like chronic obstructive pulmonary disease (COPD), is often underdiagnosed in China. Preserved Ratio Impaired Spirometry (PRISm) may represent an early, subclinical stage of this process. However, a comprehensive understanding of their clinical phenotypes, effective predictive strategies for early identification in large populations, and the role of systemic inflammation remains underexplored, particularly in the Chinese context. This study aimed to describe the clinical phenotypes of lung function impairment, identify predictive factors using machine learning, and explore associated systemic inflammation in a large-scale population screening. Methods: A prospective cross-sectional study was conducted in Hongtong County, China (2021-2024). Participants were classified into airflow obstruction, PRISm, and normal groups via portable spirometry. Using demographic, clinical, and laboratory data, we developed and validated several machine learning (ML) models to predict lung function impairment. Model performance was evaluated by the area under the receiver operating characteristic curve (AUC). Serum cytokines were measured by ELISA in matched sub-cohorts to assess systemic inflammation. Results: Among 9,284 enrolled adults, 51.0% had airflow obstruction, 6.7% had PRISm, and 42.3% were normal. We identified distinct phenotypes: the PRISm group was predominantly female with lower smoking rates but a higher risk of coronary heart disease. The airflow obstruction group was characterized by classical risk factors (older age, male sex, lower BMI, smoking) and specific renal and cerebrovascular comorbidities. The ML models identified older age, male sex, lower BMI, respiratory symptoms (cough, dyspnea), and higher creatinine and hemoglobin as key predictors, demonstrating modest performance with an AUC of 0.635 in the validation set. Immunologically, individuals with airflow obstruction or PRISm showed significantly lower serum IL-2 and higher IL-5 and IL-17A levels compared to controls. Conclusion: In a large-scale screening, individuals with airflow obstruction and PRISm present with distinct clinical phenotypes. A predictive model using simple clinical variables can help identify individuals at higher risk for lung function impairment, despite modest performance. Serum IL-2, IL-5, and IL-17A are potential biomarkers for the early recognition and understanding of airflow limitation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.